Form 4: Pacira BioSciences Director Laura Brege Acquires Stock Options and Restricted Stock Units

Director Laura Brege reports acquisition of stock options and restricted stock units in Pacira BioSciences.

Summary

• On June 12, 2024, Laura Brege, a director of Pacira BioSciences, acquired 12,179 stock options with an exercise price of $28.68, exercisable from June 12, 2025, to June 12, 2034.
• Brege also acquired 5,230 restricted stock units (RSUs) that vest on June 12, 2025, contingent upon continued service with Pacira BioSciences.
• Each RSU represents the right to receive one share of Pacira BioSciences common stock.
• Following these transactions, Brege directly owns 12,179 derivative securities and 16,552 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard Form 4 filing indicating insider transactions. The acquisition of shares and options can be seen as a positive signal, but it's not overwhelmingly significant.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates